Long-standing media company sought future-proof, fast deployment COPENHAGEN, Denmark, Feb. 13, 2025 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of Identity Governance and Administration ...

Identity security seen as key component, but organizations struggle to find the right solution COPENHAGEN, Denmark, Feb. 11, 2025 /PRNewswire/ -- Omada A/S ("Omada"), a global leader of ...

Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsSri Anantha - Vice President, ...

Q4 2024 Earnings Call Transcript February 13, 2025 CyberArk Software Ltd. beats earnings expectations. Reported EPS is $0.8, expectations were $0.71. Operator: Good morning, my name is Aaron and I ...

EYSINS, Switzerland, Feb. 10, 2025 /PRNewswire/ -- AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® Celiac ...

Inc., a leading provider of identity and access management (IAM) solutions, finds itself at a critical juncture as it navigates a complex landscape of market opportunities and challenges. The ...

The average bull market lasts nearly five years and posts an average cumulative total return of 178%, so if the current one turns out to be close to average, investors are about halfway through it ...

Within three years, he merged with IGA to ... logo over time.) Kostüme makes limited run cycle apparel in colloboration with artists. “Despite how poorly the [cycling] market is performing ...

The NFL’s Super Bowl LIX brand campaign, NFL Flag 50, which is set to debut directly after the Apple Music Halftime Show, is ...

Now, we’ve been given a much more thorough look at the integral gameplay systems and what’s in store for the next major entry in the ... after the Nobunaga samurai invaded her home village of Iga. The ...

Zilla’s AI-powered IGA capabilities will expand CyberArk’s Identity Security Platform with scalable automation.

JPMorgan analyst Anupam Rama says Vera Therapeutics (VERA) shares closed down 20% on Friday, driven by Otsuka’s announcement that the biologics ...